All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
PTCy as a prophylaxis regimen for patients with Hodgkin lymphoma
|
Data from 176 patients with Hodgkin lymphoma (HL) treated with post-transplant cyclophosphamide (PTCy) and 270 patients with conventional calcineurin inhibitor (CNI)-based graft-versus-host disease (GvHD) prophylaxis regimens were published in Blood Advances by Montori et al.1
|
| Key learnings: |
|
The incidence of chronic GvHD was lower in the PTCy cohort compared with the CNI-based cohort (25% vs 43%; p < 0.001). |
|
Patients treated with PTCy experienced a lower 2-year cumulative incidence of relapse compared with those treated with CNI-based prophylaxis (17% vs 30%; p = 0.007). |
|
Improved overall survival rates were observed with PTCy compared with CNI-based prophylaxis (85% vs 72%; p = 0.005). |
|
Progression-free survival (72% vs 53%; p < 0.001) and GvHD-free relapse-free survival rates (59% vs 31%; p < 0.001) were also higher in the PTCy cohort compared with CNI-based cohort. |
|
Overall, PTCy prophylaxis resulted in a lower incidence of GvHD, as well as improved clinical outcomes in patients with HL undergoing transplant from human leukocyte antigen-matched donors. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
